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Myocardial ischemia/reperfusion injury and resultant myocardial infarction remains a major cause of death. One of the most beneficial experimental interventions to produce cardiac protection from myocardial ischemia/reperfusion injury is termed ischemic preconditioning (IPC) \[[@CR22]\]. IPC occurs when the myocardium is exposed to brief (as short as 5 min) ischemia resulting in protection from subsequent prolonged (up to 60 min) ischemia. IPC is a biphasic event: The acute phase occurs immediately after the IPC stimulus and lasts 1--3 h and is transient \[[@CR19]\]. The delayed phase of protection is seen 12--24 h after the initial stimulus and lasts up to 72 h \[[@CR21]\]. Cardiac protection in which the cardiac protective strategy is applied at the time of reperfusion has been termed *postconditioning* \[[@CR40]\]. IPC and postconditioning are promiscuous stimuli that involve the initiation of many shared and interconnected signaling pathways \[[@CR10]--[@CR12], [@CR15]\] (Fig. [1](#Fig1){ref-type="fig"}). There is uncertainty as to how signaling molecules interact within cells to produce cardiac protection. We propose that the signal components in cardiac protection coexist and function in a lipid-rich environment (caveolae) and that the interaction of signaling molecules with caveolins is necessary for cardiac protection.Fig. 1Overview of the signaling molecules involved in cardiac protection. *ROS* reactive oxygen species, *NO* nitric oxide, *GC* guanylyl cyclase (Adapted from \[[@CR10]\])

Caveolae, or "little caves" (Fig. [2](#Fig2){ref-type="fig"}) are cholesterol- and sphingolipid-enriched invaginations of the plasma membrane \[[@CR23]\] and are a subset of lipid rafts \[[@CR29]\]. Caveolins---the structural proteins essential for caveolae formation---are present in three isoforms \[[@CR2], [@CR24]\]. Caveolin-1 and caveolin-2 (Cav-1 and Cav-2) are expressed in multiple cell types, whereas caveolin-3 (Cav-3) is found primarily in striated (skeletal and cardiac) muscle and certain smooth muscle cells \[[@CR33]\]. Caveolins are involved in multiple cellular processes, including vesicular transport, cholesterol and calcium homeostasis \[[@CR8], [@CR9], [@CR14], [@CR28], [@CR31]\], and signal transduction \[[@CR3], [@CR20], [@CR34], [@CR37]\]. Caveolins function as chaperones and scaffolds via a scaffolding domain recruiting signaling molecules to caveolae to provide direct temporal and spatial regulation of signal transduction \[[@CR32], [@CR37]\]. Caveolins can inhibit proteins by interaction with a caveolin-binding motif present in proteins, including eNOS and ERK1/2 \[[@CR5], [@CR7], [@CR16]\]. Alternatively, caveolins can promote signaling via enhanced receptor--effector coupling or enhanced receptor affinity when caveolins are upregulated or overexpressed \[[@CR6], [@CR30], [@CR38]\].Fig. 2Signaling molecules involved in cardiac protection known to localize in caveolae and interact with the scaffolding domain (*green*) of caveolin

Preconditioning and postconditioning are mediated via a complex molecular signaling cascade known as the reperfusion injury salvage kinase (RISK) pathway \[[@CR12]\]. In addition to sublethal ischemia and reperfusion, several pharmaceuticals including opioids and volatile anesthetics produce preconditioning and postconditioning via similar signaling cascades \[[@CR27]\]. Many RISK pathway molecules associate with caveolae and caveolins, including G-protein coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), Src kinases, G-proteins, H-Ras, nitric oxide synthases, protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), and MEK/ERK kinases (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR18]\]. Further evidence that caveolins are involved in cardiac protection stems from the finding that infusion of the caveolin scaffolding domain peptide of Cav-1 into ischemic/reperfused hearts increased the recovery of cardiac function \[[@CR39]\]. Subsequently, it was shown that ischemia/reperfusion injury activated mitogen-activated protein kinases, redistributed Cav-3, and downregulated expression of Cav-1, limiting the negative impact of Cav-1 on eNOS \[[@CR1]\]. This suggested a potential mechanism for IPC via increased generation of NO during lethal ischemia \[[@CR4]\]. Others showed that IPC can modulate the microenvironment of caveolae to enrich for proteins that promote cardiac protection, including eNOS and the glucose transporter GLUT-4 that translocate to caveolae after IPC \[[@CR17]\].

Caveolae and Caveolins are Essential for Cardiac Protection from Ischemia/Reperfusion Injury {#Sec2}
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We first set out to test the hypothesis that caveolae and caveolins are critical elements of the signaling pathways involved in cardiac protection from ischemia/reperfusion injury. In a novel set of experiments, we investigated the role of caveolae in IPC and opioid-receptor-mediated cardiac protection \[[@CR25]\]. In cardiac myocytes isolated from adult rats we determined protein expression and localization of the δ-opioid receptor using coimmunohistochemistry, caveolar fractionation, and immunoprecipitations. The δ-opioid receptor colocalized in fractions with Cav-3 and could be immunoprecipitated by a Cav-3 antibody. Immunohistochemistry confirmed plasma membrane colocalization of the δ-opioid receptor with Cav-3. Cardiac myocytes were subjected to simulated ischemia (2 h) or an IPC protocol (10 min ischemia, 30 min recovery, 2 h ischemia) in the presence and absence of methyl-β-cyclodextrin, which binds cholesterol and disrupts caveolae. We also assessed the cardiac protective effects of SNC-121---a selective δ-opioid receptor agonist---on cardiac myocytes with or without methyl-β-cyclodextrin and methyl-β-cyclodextrin preloaded with cholesterol. Ischemia, simulated by mineral oil layering to inhibit gas exchange, promoted cardiac myocyte cell death as assessed by trypan blue staining---a response blunted by SNC-121 or by use of the IPC protocol. Methyl-β-cyclodextrin treatment, which disrupted caveolae (as detected by electron microscopy), fully attenuated the protective effects of IPC or SNC-121, resulting in cell death comparable to that of the ischemic group. In contrast, protection was not blocked in cells incubated with cholesterol-saturated methyl-β-cyclodextrin, which maintained caveolae structure and function. These findings were the first to suggest a key role for caveolae, perhaps through enrichment of signaling molecules, in contributing to cardiac protection from ischemia/reperfusion injury.

We next investigated the role of caveolae and the specific caveolin molecules in cardiac protection. We tested the hypothesis that caveolae and Cav-3 are essential for volatile anesthetic-induced cardiac protection using cardiac myocytes from adult rats and in vivo studies in Cav-3 knockout mice (Cav-3−/−) \[[@CR13]\]. Cav-3−/− mice lack Cav-3 and caveolae in their cardiac myocyte membranes. We incubated normal adult rat cardiac myocytes with methyl-β-cyclodextrin or colchicine to disrupt caveolae formation and then exposed the myocytes to the volatile anesthetic isoflurane for 30 min at 1.4%, followed by simulated ischemia/reperfusion in a hypoxic chamber. Isoflurane protected cardiac myocytes from simulated ischemia/reperfusion, but this protection was abolished by methyl-β-cyclodextrin or colchicine. Membrane fractionation by sucrose density gradient centrifugation of myocytes treated with methyl-β-cyclodextrin or colchicine revealed that buoyant (caveolae-enriched) fractions had decreased phosphoCav-1 and Cav-3 compared to control cardiac myocytes. Cardiac protection in vivo was assessed by measurement of infarct size relative to the area at risk and cardiac troponin levels. Isoflurane induced a reduction in infarct size and cardiac troponin relative to control. Isoflurane-induced cardiac protection was abolished in Cav-3−/− mice. We concluded that caveolae and Cav-3 were critical elements involved in volatile anesthetic-induced cardiac protection from ischemia/reperfusion injury.

We also explored a specific role for Cav-1 in cardiac protection using in vitro and in vivo models of ischemia/reperfusion injury, transgenic mice, and biochemical assays \[[@CR26]\]. We found that Cav-1 mRNA and protein were expressed in adult mouse cardiac myocytes. The volatile anesthetic isoflurane protected cardiac myocytes from hypoxia-induced cell death. Hearts of wild-type (WT) mice showed rapid phosphorylation of Src and Cav-1 after isoflurane and ischemic preconditioning. The Src inhibitor PP2 reduced phosphorylation of Src (Y416) and Cav-1 in the heart and abolished isoflurane-induced cardiac protection in wild-type mice. Infarct size was reduced by isoflurane in WT mice but not Cav-1−/− mice. Cav-1−/− mice exposed to isoflurane showed significant alterations in Src phosphorylation and recruitment of C-terminal Src kinase---a negative regulator of Src---when compared to WT mice. The results indicated that activation of Src and phosphorylation of Cav-1 are critical steps in the signaling pathways involved in cardiac protection. Our recent study indicates that delayed protection is still present in Cav-1−/− but not Cav-3−/−, suggesting that the caveolae formation (dependent on Cav-3) might be a common element to both acute and delayed cardiac protection \[[@CR36]\].

Overexpression of Cav-3 Produces Innate Cardiac Protection from Ischemia/Reperfusion Injury {#Sec3}
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A key finding for our laboratories was that stimuli that can invoke cardiac protection from ischemia/reperfusion injury such as sublethal ischemia and volatile anesthetics actually alter sarcolemmal membrane ultrastructure and increase the number of formed caveolae (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR26], [@CR35]\]. Given these findings, we tested the hypothesis that cardiac myocyte-specific overexpression of Cav-3 would enhance the formation of caveolae and augment innate cardiac protection in vivo. We showed that adenovirus for Cav-3 increased caveolar formation and phosphorylation of survival kinases in cardiac myocytes in vitro. We then produced a transgenic mouse with cardiac myocyte-specific overexpression of Cav-3 using the α-myosin heavy-chain promoter (Cav-3 OE mice) and showed enhanced formation of caveolae on the cardiac myocyte sarcolemmal of these mice. Cav-3 OE mice subjected to ischemia/reperfusion injury had a significantly reduced infarct size relative to transgene-negative control mice. Innate cardiac protection in Cav-3 OE mice was similar to WT mice undergoing IPC and no increased protection was observed in preconditioned Cav-3 OE mice. Additionally, Cav-3 knockout mice did not show innate protection and showed no protection in response to preconditioning. Cav-3 OE mouse hearts had increased basal Akt and GSK3β phosphorylation comparable to WT mice exposed to IPC. Wortmannin---a PI3K inhibitor---attenuated basal phosphorylation of Akt and GSK3β and blocked cardiac protection in Cav-3 OE mice. Cav-3 OE mice had improved functional recovery and reduced apoptosis at 24 h of reperfusion following an initial 30 min of ischemia. We concluded that expression of Cav-3 is both necessary and sufficient for cardiac protection and that increased expression of caveolins has the potential to protect hearts exposed to ischemia/reperfusion injury.Fig. 3Mice underwent ischemic preconditioning (IPC, 5 min of ischemia and then reperfusion) and hearts were perfusion fixed at 15 min of reperfusion with 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 2 h at room temperature, postfixed in 1% OsO~4~ in 0.1 M cacodylate buffer (1 h) at room temperature. Control animals underwent sham surgery. Representative electron microscopy images show that IPC increases membrane invaginations that are typical features of caveolae
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Cardiac protective strategies geared toward myocardial ischemia/reperfusion injury are of major interest. It is now clear that the caveolin protein family plays a diverse and critical role in the cardiovascular system and a significant role in cardiac protective signaling. However, our understanding of the underlying mechanisms involved with caveolae, caveolins, and cardiac protection remains limited and an exciting area for active investigation. Further basic science research and eventual randomized clinical trials are needed to define the precise mechanisms and therapeutic potential of caveolins in patients at risk of myocardial ischemia.
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